Drug intelligence / Profile preview

FPI-2059

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FPI-2059 is a clinical-stage radiopharmaceutical developed by Fusion Pharmaceuticals for the treatment of solid tumors. It originated from an asset, IPN-1087, acquired from Ipsen, which Fusion subsequently modified. FPI-2059 is a small molecule designed to target Neurotensin Receptor 1 (NTSR1) and utilizes actinium-225, an alpha particle emitter, as its radioisotope. Fusion Pharmaceuticals, the developer, was acquired by AstraZeneca.

Other names: actinium-225 FPI-2059actinium225 FPI-2059actinium 225 FPI-2059Actinium Ac 225 FPI-2059

Targets

NTR1 (Nitroreductase-1)

Beyond the preview

Go deeper on FPI-2059.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPI-2059.

Explore the full profile